PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32292447-1 2020 Objective: To determine efficacy of diclofenac suppository in reducing post-ERCP pancreatitis (PEP) and identify risk factors for PEP. Diclofenac 36-46 prolyl endopeptidase Homo sapiens 95-98 33040554-2 2021 Several randomized controlled trials and meta-analyses have demonstrated the effectiveness of nonsteroidal anti-inflammatories (NSAIDs) such as diclofenac and indomethacin as a post-ERC pancreatitis (PEP) prophylaxis. Diclofenac 144-154 prolyl endopeptidase Homo sapiens 200-203 33040554-3 2021 The aim is to determine if the rectal diclofenac use reduces the PEP rate. Diclofenac 38-48 prolyl endopeptidase Homo sapiens 65-68 33040554-6 2021 Two groups were analyzed: group A (without diclofenac use) and group B (with use of diclofenac as PEP prophylaxis). Diclofenac 84-94 prolyl endopeptidase Homo sapiens 98-101 32624663-3 2020 This study investigated the difference in the incidence of PEP between intramuscular and rectal prophylactic administration of diclofenac before ERCP. Diclofenac 127-137 prolyl endopeptidase Homo sapiens 59-62 32292447-6 2020 Among 82 (49.7%) patients in diclofenac group, 8 (9.7%) developed pancreatitis while 19(22.9%) of 83(50.3%) in placebo group had PEP (p value 0.02). Diclofenac 29-39 prolyl endopeptidase Homo sapiens 129-132 25438071-9 2015 Although the risk of PEP in individuals with FPC can be reduced by using prophylactic self-expelling stents and diclofenac, it remains too high for routine screening. Diclofenac 112-122 prolyl endopeptidase Homo sapiens 21-24 31612188-3 2019 Rectal nonsteroidal anti-inflammatory drugs (specifically, 100 mg of diclofenac) have shown promising prophylactic activity in PEP. Diclofenac 69-79 prolyl endopeptidase Homo sapiens 127-130 31612188-9 2019 RESULT: Data were prospectively collected and to demonstrate the preventive effect of rectal diclofenac on PEP, a two-by-two table and chi-square test with Yates correction were used: the incidence of PEP was significantly lower (p < 0.001) in the rectal diclofenac group respect to other groups and, in the same way, the incidence of post-ERCP pain was significantly lower in the rectal diclofenac group than in the other groups (p = 0.001) and patients discharge was consequently earlier (p < 0.01). Diclofenac 93-103 prolyl endopeptidase Homo sapiens 107-110 31612188-9 2019 RESULT: Data were prospectively collected and to demonstrate the preventive effect of rectal diclofenac on PEP, a two-by-two table and chi-square test with Yates correction were used: the incidence of PEP was significantly lower (p < 0.001) in the rectal diclofenac group respect to other groups and, in the same way, the incidence of post-ERCP pain was significantly lower in the rectal diclofenac group than in the other groups (p = 0.001) and patients discharge was consequently earlier (p < 0.01). Diclofenac 93-103 prolyl endopeptidase Homo sapiens 201-204 31612188-10 2019 CONCLUSION: 100 mg dose rectal diclofenac administered 30-60 minutes before ERCP can effectively prevent PEP. Diclofenac 31-41 prolyl endopeptidase Homo sapiens 105-108 27849643-8 2017 The overall incidence of PEP was 8.6%, which occurred in five of the 124 (4%) patients who received diclofenac, seven of the 122 (5.8%) patients who received indomethacin, and 20 of the 126 (15.9%) patients who received naproxen. Diclofenac 100-110 prolyl endopeptidase Homo sapiens 25-28 27849643-11 2017 CONCLUSION: Diclofenac and indomethacin patient groups had a lower incidence of PEP than the naproxen group. Diclofenac 12-22 prolyl endopeptidase Homo sapiens 80-83